AMENDMENT TO THE CLAIMS

This listing of claims will replace all prior versions, and listings of claims in the application.

1. (Currently amended) A compound of formula Ib,



(Ib)

wherein,

R^0 is 

isoxazol-3-yl, which is unsubstituted or mono-, di- or trisubstituted independently of one another by R8, and which is additionally substituted by a monocyclic or bicyclic 4- to 15-membered heterocyclyl, containing one, two, three or four heteroatoms chosen from the group consisting of nitrogen, sulfur or oxygen, wherein, said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R8;

R8 is 1) halogen,

2) $-NO_2$,

3) -CN,

4) $-C(O)-NH_2$,

5) -OH,

6) $-NH_2$,

7) $-O-CF_3$

8) a monocyclic or bicyclic 6- to 14-membered aryl, wherein aryl is mono-, di- or trisubstituted independently of one another by halogen or $-O-(C_1-C_8)$-alkyl,

9) -(C_1-C_8)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, NH_2, -OH or a methoxy residue,

10) –O-(C_1-C_8)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, NH_2, -OH or a methoxy residue,

11) -SO_2-CH_3 or

12) –SO_2-CF_3;

~~provided that where R^0 is a monocyclic or bicyclic 6- to 14-membered aryl, then R8 is at least one halogen, -C(O)-NH_2 or -O-(C_1-C_8)-alkyl residue~~;

Q is methylene;

R^1 is hydrogen, -(C_1-C_4)-alkyl, wherein alkyl is unsubstituted or substituted one to three times by R13; -(C_1-C_3)-alkylene-C(O)-NH-R^0, -(C_1-C_3)-alkylene-C(O)-O-R10, a monocyclic or bicyclic 6- to 14-membered aryl, wherein aryl is mono-, di- or trisubstituted independently of one another by R8, a monocyclic or bicyclic 4- to 15-membered heterocyclyl, containing one, two, three or four heteroatoms chosen from nitrogen, sulfur or oxygen; -(C_1-C_3)-perfluoroalkyl, -(C_1-C_3)-alkylene-S(O)-(C_1-C_4)-alkyl, -(C_1-C_3)-alkylene-$S(O)_2$-(C_1-C_3)-alkyl, -(C_1-C_3)-alkylene-$S(O)_2$-N($R^{4'}$)-$R^{5'}$, -(C_1-C_3)-alkylene-O-(C_1-C_4)-alkyl, -(C_0-C_3)-alkylene-(C_3-C_8)-cycloalkyl, or -(C_0-C_3)-alkylene-het, wherein het is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, wherein $R^{4'}$ and $R^{5'}$ are independent of one another are identical or different and are hydrogen or -(C_1-C_4)-alkyl;

R^2 is a direct bond or –(C_1-C_4)-alkylene, or

R^1 and R3 together with the atoms to which they are bonded form a 6- to 8-membered cyclic group, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, and wherein,

said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R14; or

R^1-N-R^2-V form a 4- to 8-membered cyclic group, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,

R14 is halogen, -OH, =O, -(C_1-C_8)-alkyl, -(C_1-C_4)-alkoxy, -NO_2, -(C_0-C_4)-alkyl-C(O)-O-R^{18}, -CN, -(C_0-C_4)-alkyl-N(R^{18})-R^{21}, -(C_0-C_4)-alkyl-O-R^{18}, -(C_0-C_4)-alkyl-het, -(C_0-C_8)-alkyl-SO_2, -SO_2-(C_1-C_4)-alkyl, -SO_2-N(R^{18})-R^{21}, -C(O)-NH-(C_1-C_8)-alkyl, -C(O)-N-[(C_1-C_8)-alkyl]$_2$, -NR^{18}-C(O)-NH-(C_1-C_8)-alkyl, -C(O)-NH_2, –S-R^{18}, or –NR^{18}-C(O)-NH-[(C_1-C_8)-alkyl]$_2$,

wherein R^{18} and R^{21} are independently from each other hydrogen atom, -(C_1-C_3)-perfluoroalkyl or –(C_1-C_6)-alkyl;

V is
1) a 3- to 7-membered cyclic residue, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,
2) a 6- to14-membered aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or
3) a monocyclic or bicyclic 4- to 15-membered heterocyclyl, wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

G is a direct bond, -(CH_2)$_m$-NR^{10}-SO_2-NR^{10}-(CH_2)$_n$-, -(CH_2)$_m$-CH(OH)-(CH_2)$_n$-, -(CH_2)$_m$-, -(CH_2)$_m$-O-(CH_2)$_n$-, -(CH_2)$_m$-C(O)-NR^{10} -(CH_2)$_n$-, -(CH_2)-SO_2-(CH_2)$_n$-, -(CH_2)$_m$-NR^{10}-C(O)-NR^{10}-(CH_2)$_n$-, -(CH_2)$_m$-NR^{10}-C(O)-(CH_2)$_n$-, -(CH_2)$_m$-C(O)-(CH_2)$_n$-, -(CH_2)-S-(CH_2)$_n$-, -(CH_2)$_m$-SO_2-NR^{10}-(CH_2)$_n$-, -(CH_2)$_m$-NR^{10}-SO_2-(CH_2)$_n$-, -(CH_2)$_m$-NR^{10}-, -(CH_2)$_m$-O-C(O)-NR^{10}-(CH_2)$_n$- or –(CH_2)$_m$-NR^{10}-C(O)-O-(CH_2)$_n$-;

n and m are independently of one another identical or different and are the integers zero, 1, 2, 3, 4, 5 or 6;

M is
1) hydrogen,
2) -(C_1-C_8)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,
3) -C(O)-N(R11)-R12,
4) -$(CH_2)_m$-NR^{10},
5) a 6- to14-membered aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,
6) a monocyclic or bicyclic 4- to 15-membered heterocyclyl, wherein heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,
7) -(C_3-C_8)-cycloalkyl, wherein said cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or
8) a 3- to 7-membered cyclic residue, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

R^3 and R^4 are independent of one another are identical or different and are
1) hydrogen,
2) halogen,
3) -(C_1-C_4)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
4) -(C_1-C_3)-perfluoroalkyl,
5) phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
6) -(C_0-C_4)-alkylene-O-R19, wherein R19 is
   a) hydrogen,

b) -(C_1-C_4)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, or

c) phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

d) $-CF_3$, or

e) $-CHF_2$,

7) $-NO_2$,

8) -CN,

9) $-SO_s-R^{11}$, wherein s is 1 or 2,

10) $-SO_t-N(R^{11})-R^{12}$, wherein t is 1 or 2,

11) -(C_0-C_4)-alkylene-C(O)-R^{11},

12) -(C_0-C_4)-alkylene-C(O)-O-R^{11},

13) -(C_0-C_4)-alkylene-C(O)-N(R^{11})-R^{12},

14) -(C_0-C_4)-alkylene-N(R^{11})-R^{12},

15) $-NR^{10}-SO_2-R^{10}$,

16) $-S-R^{10}$,

17) -(C_0-C_2)alkylene-C(O)-O-(C_2-C_4)-alkylene-O-C(O)-(C_1-C_4)-alkyl,

18) -C(O)-O-C(R15, R16)-O-C(O)-R17,

19) –(C_0-C_2)alkylene-C(O)-O-(C_2-C_4)-alkylene-O-C(O)-O-(C_1-C_6)-alkyl,

20) -C(O)-O- C(R15, R16)-O-C(O)-O-R17,

21) -(C_0-C_4)-alkylene-(C_6-C_{14})-aryl, wherein aryl is mono-, di- or trisubstituted independently of one another by R13,

22) -(C_0-C_4)-alkylene-(C_4-C_{15})-heterocyclyl, wherein heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13

23) -(C_0-C_4)-alkylene-(C_3-C_8)-cycloalkyl, wherein cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

24) -(C_0-C_4)-alkylene-het, wherein het is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

25) -(C_0-C_4)-alkylene-O-CH_2-(C_1-C_3)-perfluoroalkylene-CH_2-O-(C_0-C_4)-alkyl, or

26) a residue selected from the group consisting of



and

wherein Me is methyl, or

two -OR19 residues and adjacent atoms through which they are attached form together a 5- or 6-membered ring, that is unsubstituted or substituted one, two, three or four times by R13;

R11 and R12 are independently of one another identical or different and are

1) hydrogen,
2) -(C_1-C_6)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
3) -(C_0-C_6)-alkyl-(C_3-C_8)-cycloalkyl,
4) -SO_t-R^{10}, wherein t is 1 or 2,
5) -(C_0-C_6)-alkyl-(C_6-C_{14})-aryl, wherein alkyl and aryl independently from one another are unsubstituted or mono-, di- or trisubstituted by R13,
6) -(C_1-C_3)-perfluoroalkyl,
7) -O-R^{17}, or

8) -(C_0-C_6)-alkyl-(C_4-C_{15})-heterocyclyl, wherein alkyl and heterocyclyl independently from one another are unsubstituted or mono-, di- or trisubstituted by R13, or

R11 and R12 together with the nitrogen atom to which they are bonded can form a 4- to 8-membered monocyclic heterocyclic ring which in addition to the nitrogen atom can contain one or two identical or different ring heteroatoms chosen from oxygen, sulfur and nitrogen; wherein said heterocyclic ring is unsubstituted or mono-, di- or trisubstituted independently of one another by R13;

R13 is halogen, -NO_2, -CN, =O, -OH, -CF_3, -C(O)-O-R^{10}, -C(O)-N(R^{10})-R^{20}, -N(R^{10})-R^{20}, -(C_3-C_8)-cycloalkyl, -(C_0-C_3)-alkylene-O-R^{10}, -Si-(CH_3)$_3$, -N(R^{10})-S(O)$_u$-R^{10}, wherein u is 1 or 2, -S-R^{10}, -SO_r-R^{10}, wherein r is 1 or 2, -S(O)$_v$-N(R^{10})-R^{20}, wherein v is 1 or 2, -C(O)-R^{10}, -(C_1-C_8)-alkyl, -(C_1-C_8)-alkoxy, phenyl, phenyloxy-, -O-CF_3, -(C_0-C_4)-alkyl-C(O)-O-C(R15, R16)-O-C(O)-R17, -(C_1-C_4)-alkoxy-phenyl, -(C_0-C_4)-alkyl-C(O)-O-C(R15, R16)-O-C(O)-O-R17, -(C_1-C_3)-perfluoroalkyl, -O-R15, -NH-C(O)-NH-R^{10}, -NH-C(O)-O-R^{10}, or a residue selected from the group consisting of



and ;

R^{10} and R^{20} are independently of one another hydrogen, -(C_1-C_6)-alkyl, -(C_0-C_4)-alkyl-OH, -(C_0-C_4)-alkyl-O-(C_1-C_4)-alkyl or -(C_1-C_3)-perfluoroalkyl;

R15 and R16 are independently of one another hydrogen, -(C_1-C_6)-alkyl, or together with the carbon atom to which they are bonded they can form a 3- to 6 membered carbocyclic ring which is unsubstituted or substituted one to three times by R^{10}; and

R17 is -(C_1-C_6)-alkyl, -(C_1-C_6)-alkyl-OH, -(C_1-C_6)-alkyl-O-(C_1-C_6)-alkyl, -(C_3-C_8)-cycloalkyl, -(C_1-C_6)-alkyl-O-(C_1-C_8)-alkyl-(C_3-C_8)-cycloalkyl, -(C_1-C_6)-alkyl-(C_3-C_8)-cycloalkyl, wherein said cycloalkyl ring is unsubstituted or substituted one, two or three times by -OH, -O-(C_1-C_4)-alkyl or R^{10}; or

a stereoisomeric form or a mixtures thereof in any ratio, or a physiologically tolerable salt thereof.

2-11. (Cancelled)

12. (Previously presented) A compound according to claim 1, which is:

3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-3H-imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide;

5-Chloro-3-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-phenyl-3H-imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide;

3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-methyl-3H-imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide;

3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-ethyl-5-methyl-3H-imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide;

3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-iodo-5-methyl-3H-imidazole-4- carboxylic acid (1-isopropyl-piperidin-4-yl)-amide;

3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-methoxymethyl-3H-imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide;

3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-cyclopropyl-3H-imidazole-4- carboxylic acid (1-isopropyl-piperidin-4-yl)-amide;

3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-(2,6-difluoro-phenyl)-3H-imidazole- 4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide;

3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-cyclopentyl-3H-imidazole-4- carboxylic acid (1-isopropyl-piperidin-4-yl)-amide;

3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-(2-methoxy-ethyl)-3H-imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide;

3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-(2,6-dichloro-phenyl)-3H-imidazole- 4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide;

3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-isopropyl-3H-imidazole-4- carboxylic acid (1-isopropyl-piperidin-4-yl)-amide;

3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-pyridin-2-yl-3H-imidazole-4- carboxylic acid (1-isopropyl-piperidin-4-yl)-amide;

3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-methyl-2-phenyl-3H-imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide;

3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-pyridin-3-yl-3H-imidazole-4- carboxylic acid (1-isopropyl-piperidin-4-yl)-amide;

3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-(2-methyl-thiazol-4-yl)-3H- imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide;

3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-ethanesulfonyl-3H-imidazole-4- carboxylic acid (1-isopropyl-piperidin-4-yl)-amide;

3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-methyl-3H-imidazole-2,4- dicarboxylic acid 2-amide 4-[(1-isopropyl-piperidin-4-yl)-amide];

2-Bromo-3-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-methyl-3H-imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide;

3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-(2-methoxy-phenyl)-5-methyl-3H-imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide;

3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-(3-trifluoromethyl-phenyl)-3H- imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide;

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-imidazole-2-carboxylic acid ethyl ester;

3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-[2-(2-methoxy-ethoxy)-ethoxymethyl]-3H-imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide;

3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-(2-methoxy-ethoxymethyl)-3H-imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide; or

3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-(perhydro-1,4-oxazepine-4-carbonyl)-3H-imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide.

13. (Currently amended) A process for the preparation of a compound according to claim 1 comprising condensing a compound of formula **29** with a compound of formula $HR^{8'}$ to give a

compound of formula **30** and converting the compound of formula **30** into the compound of formula Ib,



29



30



29



30

wherein the residue $R^{8'}$ represents $-N(R^1)-R^2-V-G-M$ as defined in claim 1, or a group which can be subsequently transformed into said $-N(R^1)-R^2-V-G-M$, and where the residue R^{53} denotes the group $-Q-R^o$ as defined in claim 1 or can denote a group which can be subsequently transformed into said group $-Q-R^o$, and where the group $-C(O)-R^{52}$ is a carboxylic acid group or

derivative thereof, and where the groups R^{1a} and R^{1b} in the formulae **29** and **30** have the corresponding definitions of R^3 and R^4 in formula Ib as defined in claim 1, optionally with functional groups in them which are in protected form or in the form of precursor groups.

14. (Previously presented) A pharmaceutical preparation, comprising at least one compound of the formula I according to claim 1 or a stereoisomeric form or a mixture thereof in any ratio, or a physiologically tolerable salt thereof, and a pharmaceutically acceptable carrier.

15-17. (Cancelled)

18. (Currently amended) The compound according to claim 1, wherein,

R^0 is isoxazol-3-yl, which is substituted by a residue selected from the group consisting of thienyl, 2-thienyl and 3-thienyl, wherein said residue is unsubstituted or mono- or disubstituted independently of one another by R8;

R8 is fluorine, chlorine or bromine;

Q is methylene;

R^1 is hydrogen;

R^2 is a direct bond or methylene;

V is 1) a residue selected from the group consisting of azaindolyl, 1H-pyrrolopyridyl, azetidine, 1,4-diazepane, isoxazole, isoquinoline, piperazine, piperidine, pyrazine, pyridazine, pyrimidine, pyrrolidine, quinazoline, quinoline or tetrahydropyrane,
wherein said residue is unsubstituted or mono- or disubstituted independently of one another by R14, or

2) phenyl, that is unsubstituted or mono- or disubstituted independently of one another by R14; or

R^1-N-R^2-V forms azetidine, pyrrolidine, piperidine or piperazine;

R14 is fluorine, chlorine, methyl, ethyl, $-NH_2$ or $-SO_2-CH_3$;

G is a direct bond;

M is a residue selected from the group consisting of hydrogen, (C_2-C_4)-alkyl, azepanyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, imidazolyl, ketomorpholinyl, morpholinyl, [1,4]oxazepanyl, phenyl, piperidinyl, piperidonyl, pyrazinyl, pyrazolyl,

pyridazinyl, pyridinyl, pyrimidyl, pyrrolidinyl, 1,4,5,6-tetrahydro-pyridazinyl, and tetrahydropyranyl, wherein said residue is unsubstituted or mono- or disubstituted independently of one another by R14;

R^3 and R^4 are independent of one another, are identical or different, and are

1) hydrogen,
2) fluorine or chlorine,
3) -(C_1-C_4)-alkyl, wherein said alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
4) -(C_1-C_3)-perfluoroalkyl,
5) phenyl, wherein said phenyl is unsubstituted or mono-, di- or trisubstituted, independently of one another, by R13,
6) -(C_0-C_2)-alkylene-O-R19, wherein R19 is
   a) hydrogen,
   b) -(C_1-C_4)-alkyl, wherein said alkyl is unsubstituted or mono-, di- or trisubstituted, independently of one another, by R13, or
   c) phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted, independently of one another, by R13,
   d) $-CF_3$, or
   e) $-CHF_2$,
8) -CN,
9) $-SO_s-R^{11}$, wherein s is 1 or 2,
10) $-SO_t-N(R^{11})-R^{12}$, wherein t is 1 or 2,
11) -(C_0-C_4)-alkylene-C(O)-R^{11},
12) -(C_0-C_4)-alkylene-C(O)-O-R^{11},
13) -(C_0-C_4)-alkylene-C(O)-N(R^{11})-R^{12},
14) -(C_0-C_4)-alkylene-N(R^{11})-R^{12},
15) $-NR^{10}-SO_2-R^{10}$,
17) -(C_0-C_2)alkylene-C(O)-O-(C_2-C_4)-alkylene-O-C(O)-(C_1-C_4)-alkyl,
18) -C(O)-O-C(R15, R16)-O-C(O)-R17,

19) -(C_0-C_2)alkylene-C(O)-O-(C_2-C_4)-alkylene-O-C(O)-O-(C_1-C_6)-alkyl,

20) -C(O)-O- C(R15, R16)-O-C(O)-O-R17,

23) -(C_0-C_3)-alkylene-(C_3-C_6)-cycloalkyl, or -(C_0-C_4)-alkylene-(C_3-C_6)-cycloalkyl, that is unsubstituted or mono-, di- or trisubstituted, independently of one another, by R13,

24) het, wherein said het is pyridyl or thiazolyl, that is unsubstituted or mono-, di- or trisubstituted, independently of one another, by R13, or

25) -(C_0-C_3)-alkylene-O-CH_2-CF_2-CH_2-O-(C_0-C_3)-alkyl, -(C_0-C_3)-alkylene-O-CH_2-CF_2-CF_2-CH_2-O-(C_0-C_3)-alkyl, or -(C_0-C_3)-alkylene-O-CH_2-(C_1-C_3)-perfluoroalkylene-CH_2-OH, or

26) a residue selected from the group consisting of



wherein Me is methyl;

R11 and R12 are, independently of one another, identical or different and are

1) hydrogen,

2) -(C_1-C_4)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted, independently of one another, by R13,

3) -(C_0-C_6)-alkyl-(C_3-C_6)-cycloalkyl,

7) -O-R^{17}, or

8) -(C_0-C_6)-alkyl-heterocyclyl, wherein alkyl and heterocyclyl, independently from one another, are unsubstituted or mono-, di- or trisubstituted by R13 and wherein heterocyclyl is azetidine, imidazolidine, morpholine, (1,4)-oxazepane or pyrrolidine, or

R11 and R12, together with the nitrogen atom to which they are bonded, form azetidine, imidazolidine, morpholine, (1,4)-oxazepane, 1,4-oxazepine, piperazine, piperidine, pyrrolidine or thiomorpholine;

R13 is fluorine, chlorine, -CN, =O, -OH, $-CF_3$, $-C(O)-O-R^{10}$, $-C(O)-N(R^{10})-R^{20}$, $-N(R^{10})-R^{20}$, $-(C_3-C_6)$-cycloalkyl, $-(C_0-C_3)$-alkylene-O-R^{10}, $-Si-(CH_3)_3$, $-S-R^{10}$, $-SO_2-R^{10}$, $-(C_1-C_4)$-alkyl, $-(C_1-C_3)$-perfluoroalkyl, or a residue selected from the group consisting of



and

wherein Me is methyl;

R^{10} and R^{20} are, independently of one another, hydrogen, $-(C_1-C_4)$-alkyl, or $-(C_1-C_3)$-perfluoroalkyl; and

R^{15} and R^{16} are, independently of one another, hydrogen, $-(C_1-C_4)$-alkyl, or together form cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, wherein each ring is unsubstituted or substituted one to three times by R^{10},

or a stereoisomeric form or a mixture thereof in any ratio, or a physiologically tolerable salt thereof.